DrugPatentWatch Database Preview
Drugs in Development Information for DCC-2618
Drug Development Status for DCC-2618: Patents, clinical trial progress, indications
DCC-2618 is an investigational drug.
There have been 23 clinical trials for DCC-2618.
The most recent clinical trial was a Phase 3 trial, which was initiated on October 1st 2009.
The most common disease conditions in clinical trials are Gastrointestinal Stromal Tumors, Neoplasms, and Lymphoma. The leading clinical trial sponsors are Deciphera Pharmaceuticals LLC, National Heart, Lung, and Blood Institute (NHLBI), and Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD).
Summary for DCC-2618
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 2 |
| WIPO Patent Applications | 1 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 3 (2009-10-01) |
| Vendors | 7 |
Recent Clinical Trials for DCC-2618
| Title | Sponsor | Phase |
|---|---|---|
| A Study of Rebastinib (DCC-2036) in Combination With Carboplatin in Patients With Advanced or Metastatic Solid Tumors | Deciphera Pharmaceuticals LLC | Phase 1/Phase 2 |
| A Study of DCC-2618 vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib | Deciphera Pharmaceuticals LLC | Phase 3 |
| A Phase 1b/2 Study of Rebastinib (DCC-2036) in Combination With Paclitaxel in Patients With Advanced or Metastatic Solid Tumors | Deciphera Pharmaceuticals LLC | Phase 1/Phase 2 |
Clinical Trial Summary for DCC-2618
Top disease conditions for DCC-2618
Top clinical trial sponsors for DCC-2618
US Patents for DCC-2618
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
